Stay updated on Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.

Latest updates to the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe record for the high-risk ocular melanoma study is displayed, including its treatment plan, eligibility criteria, study locations, and outcome measures, where an error page appeared before.SummaryDifference53%

- Check19 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0. The study record remains inaccessible on this page.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates and FAQs.SummaryDifference1%

- Check32 days agoChange DetectedThe footer now shows site revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer’s ClinicalTrials.gov revision number changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check60 days agoChange DetectedThe study page now displays a 403 Forbidden error instead of the usual study record content. This signals an access restriction or server issue impacting the NCT03528408 page.SummaryDifference19%

Stay in the know with updates to Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.